Lung Cancer

FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients

Updated Lung Cancer Guidelines Acknowledge Former Smoker's Risk Of Lung Cancer Never Disappears — 5M More Americans Eligible For Screening

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors

Updated Lung Cancer Guidelines Acknowledge Former Smoker's Risk Of Lung Cancer Never Disappears — 5M More Americans Eligible For Screening

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent

Boehringer Ingelheim Scraps Lung Cancer Program With CureVac

Lung Cancer Recent News

Oncocyte Shares Fall On Posting Wider Than Expected Q2 Loss

BeyondSpring Stock Is Up More than 300%: What You Need To Know?

BeyondSpring Inc (NASDAQ: BYSI) is trading over 300% up during premarket in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in combination with docetaxel.

Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer

Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients

Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation

Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings

AstraZeneca Unveils 5-Year Survival Data for Imfinzi in Lung Cancer Patients

Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China

Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer

AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer

JNJ's Rybrevant Scores FDA Approval In Lung Cancer Patients With EGFR Exon 20 Mutation

Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda

Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study

AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer

Pulmatrix Stock Is Trading Lower After JNJ's Lung Cancer Initiative Terminates PUR1800 Licensing Pact

FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer

Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China

China's regulatory authorities have signed off on Lee's

G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients

AstraZeneca Lung Cancer Drug Gets EU Approval

AstraZeneca Plc’s (NYSE: AZN) developmental drug – Imfinizi, has been approved by the European Commission after the Phase 3 clinical trial yielded positive results.

Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Sponsored

Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy

AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial

The Bull Thesis For Merck Is Evaporating